Effects of S-adenosyl-L-methionine on the invasion and migration of head and neck squamous cancer cells and analysis of the underlying mechanisms

LAURA MOSCA¹, MICHELE MINOPOLI², MARTINA PAGANO¹, FRANCESCA VITIELLO¹, MARIA VINCENZA CARRIERO², GIOVANNA CACCIAPUOTI³ and MARINA PORCELLI¹

¹Dipartimento di Medicina di Precisione, Università della Campania ‘Luigi Vanvitelli’, I-80138 Napoli; ²Unità Progressione Neoplastica, Istituto Nazionale Tumori-IRCCS ‘Fondazione G. Pascale’, I-80131 Napoli, Italy

Received October 22, 2019; Accepted February 13, 2020

DOI: 10.3892/ijo.2020.5011

Abstract. S-Adenosyl-L-methionine (AdoMet) is the principal methyl donor in transmethylation reactions fundamental to sustaining epigenetic modifications. Over the past decade, AdoMet has been extensively investigated for its anti-proliferative, pro-apoptotic and anti-metastatic roles in several types of human cancer. Head and neck squamous cell carcinoma (HNSCC) is the sixth most common type of cancer worldwide, and is an aggressive type of cancer that is associated with a high recurrence rate, metastasis and poor treatment outcomes. The present study demonstrates, for the first time, to the best of our knowledge, that AdoMet induces cell cycle arrest and inhibits the migratory and invasive ability of two different HNSCC cell lines, oral Cal-33 and laryngeal JHU-SCC-011 cells. In both cell lines, AdoMet attenuated cell cycle progression, decreased the protein level of several cyclins and downregulated the expression of p21 cell cycle inhibitor. Moreover, AdoMet was able to inhibit Cal-33 and JHU-SCC-011 cell migration in a dose-dependent manner after 24 and 48 h, respectively, and also induced a significant reduction in the cell invasive ability, as demonstrated by Matrigel invasion assay monitored by the xCELLigence RTCA system. Western blot analysis of several migration and invasion markers confirmed the inhibitory effects exerted by AdoMet on these processes and highlighted AKT, β-catenin and small mothers against decapentaplegic (SMAD) as the main signaling pathways modulated by AdoMet. The present study also demonstrated that the combination of AdoMet and cisplatin synergistically inhibited HNSCC cell migration. Taken together, these findings demonstrate that the physiological compound, AdoMet, affects the motility and extracellular matrix invasive capability in HNSCC. Thus, AdoMet may prove to be a good candidate for future drug development against metastatic cancer.

Introduction

Head and neck squamous cell carcinoma (HNSCC) is an aggressive life-threatening disease that constitutes 90% of head and neck carcinoma (HNC). HNSCC represents 3.5% of all cancers, and is one of the most common type of cancer worldwide despite significant progress in both early diagnosis and therapy. HNC originates from the mucosal epithelia of the upper aerodigestive tract, including the tongue, lip, salivary glands, sinuses, oral cavity, pharynx, larynx and thyroid (1,2). Over the past few years, although advanced therapies have been applied for the treatment of HNC, the 5-year survival rate has not increased significantly (3,4). Thus, there is an urgent need for the identification of new molecules with antitumor activity and less therapeutic toxicity than the currently used drugs and which are, at the same time, effective against HNC. In this regard, the identification and development of naturally occurring compounds may greatly contribute to this request.

S-Adenosyl-L-methionine (AdoMet, also known as SAM) is a widely naturally-occurring sulfonium compound that plays a primary role in cellular metabolism, since it is involved in a variety of important biochemical processes being indeed, the link to three key metabolic pathways: transmethylation, polyamine synthesis and transsulfuration (5-7). Over the past few decades, a number of in vitro and in vivo studies have demonstrated the involvement of AdoMet in various cellular processes, including proliferation, differentiation, cell cycle regulation and apoptosis, demonstrating that the sulfonium...
compound exerts pleiotropic effects on signal transduction in a variety of cell types and that AdoMet is able to halt the progression of several human tumors (8-13).

The development of metastases is a multistep process that requires active and specifically localized extracellular proteolysis, as well as the activation of a series of physiological and biochemical processes that govern the migration from the primary tumor site, invasion through the basement membrane, the entry of metastatic cells into blood vessels and finally, localization to the second site (14). Despite significant progress regarding potential therapeutic targets aimed at improving survival, the median time to mortality for patients affected by metastatic HNSCC is approximately 4 months (15). Therefore, the development of novel strategies aimed at preventing the migration and extracellular invasion of HNSCC is urgently required.

There is emerging evidence to document the involvement of AdoMet in the regulation of genes responsible for cell invasion and metastasis (16-19) and several research groups have investigated in depth the epigenetic regulation induced by AdoMet on the methylation status of genes involved in invasion and metastases processes, including the urokinase-type plasminogen activator (uPA) and matrix metalloproteinases (MMPs) (16,19). It has been demonstrated that the treatment of highly invasive MDA-231 breast cancer cells and PC-3 prostate cancer cells with AdoMet, significantly inhibits uPA and MMP2 expression, resulting in the potent inhibition of tumor cell invasion in vitro and tumor growth and metastasis in vivo (16,17). Furthermore, Chik et al demonstrated that AdoMet synergizes with the DNA methylation inhibitor, 5-aza-2-deoxycytidine, to suppress uPA expression, thereby blocking MDA-MB-231 cell invasiveness (18). Another study demonstrated that in the highly invasive SW-620 colorectal cancer cell line, treatment with the sulfonium compound exerts pleiotropic effects on signal transduction in a variety of cell types and that AdoMet is able to halt the progression of several human tumors (8-13).

In light of these data, the present study investigated the effects of AdoMet on cell proliferation, migration and invasion in HNSCC, and also aimed to elucidate the underlying mechanisms. The findings of this study demonstrate that AdoMet potently inhibits the migration and invasion of two different types of HNSCC cells, oral Cal-33 and laryngeal JHU-SCC-011 cells through the modulation of the AKT, β-catenin and SMAD signaling pathways. Moreover, the synergistic effects of AdoMet and cisplatin on cell migration are reported via the evaluation of wound recovery. Taken together these results highlight AdoMet as a potential candidate for the development of novel treatment strategies for patients with HNSCC.

Materials and methods

**Reagents.** AdoMet was obtained from New England BioLabs, Inc. and prepared as previously described (13). The Annexin V-fluorescein isothiocyanate (V-FITC) Apoptosis Detection kit was purchased from eBioscience; Thermo Fisher Scientific, Inc. Tissue culture dishes were purchased from Corning Inc. Monoclonal antibodies (mAbs) to p21 (#2947S), p53 (#2524S), β-actin (#3700S), β-catenin (#4840S), AKT (#2926S), phospho-AKT(#2965S),cyclinE1(#4129S),cyclinA2(#4656S), cyclin D1 (#2978S), phospho-cdc25C (#4901S), vimentin (#5741S), E-cadherin (#14472S), phospho-SMAD3 (#9520S), SMAD3 (#9523S) and polyclonal antibodies (polyAbs) to cyclin B1 (#4138S), SMAD2 (#3102S), phospho-SMAD2 (#3104S), MMP2 (#4022S) were purchased from Cell Signaling Technology, Inc.; uPA (AB2335602, cat. no. 119) polyAb was obtained from American Diagnostica, Inc., while mAbs directed to N-cadherin (05-915) and MMP9 (AB6001) were purchased from Merck Millipore. PolyAb to cdc25c (sc-13138) was purchased from Santa Cruz Biotechnology, Inc. Goat anti-rabbit IgG Alexa Fluor647 was obtained from Abcam. Horseradish peroxidase (HRP)-conjugated goat anti-mouse (GtxMu-003-DHRPX) and HRP-conjugated goat anti-rabbit (GtxRb-003-DHRPX) secondary antibodies were obtained from ImmunoReagents Inc. All buffers and solutions were prepared with ultra-high quality water. All reagents were of the purest commercial grade.

**Cells and cell culture.** The HNC cell lines, Cal-33 (oral squamous cancer cell line) and JHU-SCC-011 (laryngeal squamous cell carcinoma line) were obtained from the American Type Culture Collection (ATCC). The cells were cultured at 37°C in a 5% CO₂ humidified atmosphere and grown in RPMI supplemented with 10% heat-inactivated FBS, 100 U/ml penicillin, 100 µg/ml streptomycin and 1% L-glutamine.

**Flow cytometry for the analysis of apoptosis.** Annexin V-FITC was used in conjunction with the vital dye propidium iodide (PI) as previously described (13) to distinguish apoptotic (Annexin V-FITC-positive, PI-negative) from necrotic (Annexin V-FITC-negative, PI-positive) cells (23). The detection of viable cells, early apoptotic cells and necrotic cells was performed using a BD Accuri™ C6 flow cytometer (BD Biosciences). For each sample, 20,000 events were acquired. Analysis was carried out by triplicate determination on at least 3 separate experiments.

**Preparation of cell lysates.** Oral cancer cells Cal-33 and JHU-SCC-011 cells, grown at 37°C for 24 and 48 h with or without AdoMet treatment, were collected by centrifugation, washed twice with ice-cold PBS and the pellet was lysed using 100 µl RIPA Buffer. Following incubation on ice for 30 min, the samples were centrifuged at 18,000 x g in an Eppendorf microcentrifuge for 30 min at 4°C and the supernatant was recovered. The protein concentration was determined using
the Bradford method (24) and compared with the BSA standard curve.

**Western blot analysis.** Equal amounts of cell proteins were separated by SDS-PAGE (separating gel, 10 or 12%; stacking gel, 5%) and electrotransferred onto nitrocellulose membranes by Trans blot turbo (Bio-Rad Laboratories, Inc.). The mass of protein loaded per lane was 10-50 µg. Membrane was washed in TBST (10 mM Tris, pH 8.0, 150 mM NaCl, 0.05% Tween-20), and blocked with TBST supplemented with 5% non-fat dry milk. Thereafter, the membranes were incubated overnight with the different primary antibodies at 4°C in TBST and 5% non-fat dry milk, washed and incubated for 1 h at room temperature with HRP-conjugated secondary antibodies. All primary antibodies were used at a dilution of 1:1,000, and all secondary antibodies were used at a 1:5,000 dilution. Blots were then developed using enhanced chemiluminescence detection reagents ECL (Cyanagen,) and exposed to X-ray film. All films were scanned using ImageJ software (National Institutes of Health).

**Flow cytometric analysis of the cell cycle.** The Cal-33 and JHU-SCC-011 cells were seeded in 6-well plates at a density of 75x10^4 cells/well and 30x10^4 cells/well, respectively. The following day, the cells were treated with 300 µM AdoMet. The Cal-33 and JHU-SCC-011 cells were recovered with trypsin-EDTA after 24 and 48 h, respectively, washed in PBS and stained in a PI solution (50 µg/ml PI, 0.1% sodium citrate, 25 µg/ml RNase A, 0.1% triton in PBS) for 1 h at 4°C in the dark. Flow cytometric analysis was performed using a BD Accuri™ C6 flow cytometer (BD Biosciences). To evaluate cell cycle progression, PI fluorescence was collected as FL3-A (linear scale) using ModFIT software (Verity Software House). For each sample at least 20,000 events were analyzed in at least 3 different experiments giving a standard deviation (SD) <5%.

**Fluorescence microscopy.** To visualize the polymerized F-actin, cells (~2x10^4/sample) were seeded on glass coverslips and cultured in growth medium in the absence (control) or presence of 300 µM AdoMet. After 24 and 48 h, the slides were washed with PBS, fixed with 2.5% formaldehyde, permeabilized with 0.1% Triton X-100 for 10 min at 4°C, and incubated with 0.1 µg/ml rhodamine-conjugated phalloidin (Sigma-Aldrich; Merck KGaA) for 40 min at 23°C (25). Nuclear staining was performed with the 10 mM 4-6-diamidino-2-phenylindole (DAPI) dye (#228549, Abcam) for 5 min at 23°C. Finally, coverslips were mounted using 20% (w/v) Mowiol, and visualized with an Axiovert 200 M fluorescence inverted microscope connected to a video camera (Carl Zeiss AG).

**Invasion kinetic of cells monitored in real-time.** This assay was performed using E-16-well plates and the xCELLigence Real-Time Cell Analysis (RTCA) technology as previously described (26). This technology measures impedance changes caused by the gradual increase in electrode surface occupation by cells during the course of time and provides a Cell Index value which is proportional to the number of adherent cells. The bottom wells were coated with 20 µg/well Matrigel diluted in serum-free medium. Matrigel was allowed to polymerize for 1 h at 37°C prior to seeding the cells (~1x10^4 cells/well) suspended in serum-free medium (control) or growth medium. Cells that cross the Matrigel adhere to the bottom of plates causing impedance changes, which are proportional to the number of invading cells. Matrigel invasion was monitored in real-time for 24 h and impedance changes were recorded and expressed as a cell index value. Slopes represent the change rate of cell index generated in a 3 to 20-h time frame. The experiments were performed 3 times in quadruplicate.

**Migration process evaluated by scratch-wound assay.** The Cal-33 and JHU-SCC-011 cells were seeded in the appropriate number in a 6-well culture plates until 100% confluence was reached in 24 h and treated with 200 and 300 µM AdoMet for 24 and 48 h, respectively or with 300 µM AdoMet alone or in combination with 0.18 or 0.36 µM cisplatin (cDDP) (Sigma-Aldrich; Merck KGaA). Following treatment, in a sterile environment, a 200 µl pipette tip was used to manually press against the top of the tissue culture plate and a vertical wound down was rapidly created through the confluent cellular monolayer. Carefully, medium and cell debris were aspirated away, replaced with 2 ml of serum-free RPMI and initial images of the wounds were captured using a microscope (Leica Microsystems GmbH) corresponding to time zero (T0). Following 24 h (T1) of treatment, snapshot images were captured to examine for wound closure. The wound areas of the control and treated cells were quantified using ImageJ software 1.48v.

**Statistical analysis.** The results are expressed as the means of at least 3 independent experiments performed in quadruplicate, unless otherwise indicated. Data are expressed as the means ± SD. The means were compared using analysis of variance (ANOVA) plus the Bonferroni correction. A P-value <0.05 was considered to indicate a statistically significant difference.

**Results**

**Effects of AdoMet on the apoptosis of Cal-33 and JHU-SCC-011 cells.** In a previous study by the authors, to the best of our knowledge, the mechanisms underlying the anti-tumor effect of AdoMet on HNSCC were reported for the first time, demonstrating that AdoMet was able to induce apoptosis, involving a caspase-dependent mechanism paralleled by an increased Bax/Bcl-2 ratio in Cal-33 and JHU-SCC-011 cells following 48 and 72 h of treatment, respectively (13).

In order to evaluate the effects of AdoMet prior to the induction of apoptotic cell-death, the Cal-33 and JHU-SCC-011 cells were treated with 300 µM AdoMet, and the apoptotic process was evaluated after 24 and 48 h, respectively, by fluorescence-activated cell sorting (FACS) analysis after double labeling with Annexin V-FITC and PI. In the absence of any treatment, very few apoptotic cells were found in both cell populations (Fig. 1, control).

The Cal-33 cells treated with 300 µM AdoMet for 24 h, exhibited an approximately 10% greater number of apoptotic cells compared to the control group (Fig. 1A), while the JHU-SCC-011 cells treated with 300 µM AdoMet for 48 h exhibited an approximately 3% greater number of apoptotic
MOSCA et al.: ADOMET AFFECTS THE MIGRATION AND INVASION OF HEAD AND NECK CANCER CELLS

Figure 1. Representative dot plots and histogram of both Annexin V-FITC and PI-stained HNSCC cells. (A) Cal-33 and (B) JHU-SCC-011 cells were treated or not (control) with 300 µM AdoMet for 24 and 48 h, respectively. Apoptosis was then evaluated by FACS analysis. In the different quadrants the percentages of cells are reported: viable cells, lower left quadrant (Q4); early apoptotic cells, bottom right quadrant (Q3); late apoptotic cells, top right quadrant (Q2); non-viable necrotic cells, upper left quadrant (Q1). For each sample 2x10^4 events were acquired. Analysis was carried out by triplicate determination of at least 3 separate experiments. Data are presented as means ± SD. *P<0.05 vs. control. HNSCC, head and neck squamous cell carcinoma; AdoMet, S-adenosyl-L-methionine.

AdoMet promotes the cell cycle arrest of Cal-33 and JHU-SCC-011 cells. In order to determine whether AdoMet treatment promotes cell cycle arrest, cell cycle progression was analyzed by flow cytometry in the Cal-33 and JHU-SCC-011 cells treated with 300 µM AdoMet for 24 and 48 h, respectively. As shown in Fig. 2A, AdoMet induced the marked accumulation of Cal-33 cells in the S/G2M phase with an increase from 47.6 to 61.9%, while the percentage of cells in the G1 phase decreased from 50.2 to 33.9%. A different effect was observed with the JHU-SCC-011 cells. Indeed, as shown in Fig. 2B, following AdoMet treatment, the G1 and G2/M phase populations decreased from 44.6 to 28.4% and from 14.7 to 7.6%, respectively, with a concomitant significant increase from 36.1 to 61% of cells in the S phase. These results demonstrate that AdoMet is able to modulate cell cycle progression of HNSCC cells.

To further investigate the effects of AdoMet on cell cycle distribution, the expression level of several key cell cycle regulators, such as cyclin D1, E1, A2 and B1 was examined by western blot analysis. As shown in Fig. 2C and 2D, a dose-dependent decrease in the expression of cyclin B1, E1 and D1 was observed in the Cal-33 and JHU-SCC-011 cells, respectively following treatment with AdoMet compared to the untreated cells. The level of cyclin A2 was shown to decrease only with the 300 µM concentration of AdoMet in the Cal-33 cells in (Fig. 2C), while a dose-dependent decrease was observed in the expression of cyclin A2 in the JHU-SCC-011 cells. These findings suggest that AdoMet attenuated cell proliferation via the downregulation of cyclin expression. Subsequently, the expression levels of cdc25C, phospho-cdc25C, p53 and the cyclin-dependent inhibitor, p21, were examined. The
Figure 2. Effects of AdoMet on cell cycle of HNSCC cells. FACS analysis of Cal-33 and JHU-SCC-011 cells treated or not (control) with 300 µM AdoMet for 24 and 48 h, respectively. FACS analysis was then performed. Representative FACS histograms of PI-stained (A) Cal-33 and (B) JHU-SCC-011 cells. On the right bar diagrams are presented showing percentage of cells in each phase of the cell cycle. Data represent the average of 3 independent experiments. The means ± SD are shown. For each sample at least 2x10⁴ events were analyzed. The protein levels of cell cycle-regulatory proteins in (C) Cal-33 and (D) JHU-SCC-011 cells treated or not (control) with 200 µM AdoMet or 300 µM AdoMet for 24 and 48 h respectively, were measured by western blot analysis and the relative densitometric analyses are reported. Data, representative of 3 experiments performed with 3 different cellular preparations, are expressed as the means ± standard deviation and are reported as a percentage of protein expression of the untreated control (100%). *P<0.05 vs. control. The housekeeping protein, β-actin, was used as a loading control. HNSCC, head and neck squamous cell carcinoma; AdoMet, S-adenosyl-L-methionine.
results revealed a substantial dose-dependent increase in the phospho-cdc25C/cdc25C ratio in the Cal-33 cells, while no significant change was detected in the JHU-SCC-011 cells. Notably, p21 expression was significantly decreased in both cell lines following AdoMet treatment, while the expression of p53, which is mutated in the Cal-33 cells, did not appear to be modified in the JHU-SCC-011 cells, indicating that the AdoMet-induced cell cycle arrest is a p53/p21-independent process.

Effects of AdoMet on the cytoskeletal organization and migration of Cal-33 and JHU-SCC-011 cells. In order to investigate the early intracellular effects occurring during AdoMet treatment, cytoskeletal organization and the motility of Cal-33 and JHU-SCC-011 cells exposed to 300 µM AdoMet for 24 and 48 h, respectively were analyzed. As revealed by the rhodamine-phalloidin staining of F-actin polymerization, in the absence of AdoMet, both the Cal-33 and JHU-SCC-011 cells exhibited a well-organized cytoskeleton with condensed aggregates localized below the membrane (Cal-33 cells) or stress fibers parallel to the longitudinal axis of the cells (JHU-SCC-011 cells). Cell exposure to AdoMet did not significantly modify the cytoskeletal organization of either the Cal-33 and JHU-SCC-011 cells (Fig. 3A and B). Conversely, AdoMet decreased the migration of the Cal-33 and JHU-SCC-011 cells in a wound healing experiment monitored for 24 h. In both cases, the wounds disappeared after 24 h in the absence of AdoMet, as shown by the microscopy images of the same field recorded at time 0 and after 24 h (Fig. 3C and D). Cell exposure to 200 and 300 µM AdoMet for 24 h led to an approximately 24 and 40% reduction, respectively, in the Cal-33 wound closure (Fig. 3C and D). Of note, the spreading of the JHU-SCC-011 cells was markedly reduced by AdoMet treatment for 48 h. Indeed, treatment with 200 and 300 µM AdoMet led to a 50 and 70% reduction in wound closure, respectively (Fig. 3D and F). These findings thus indicate that AdoMet inhibits the migration of both HNSCC lines, without affecting cytoskeletal organization.

AdoMet affects the invasion of Cal-33 and JHU-SCC-011 cells on Matrigel. Since cell motility is a prerequisite for the acquisition of an invasive phenotype, the effects of AdoMet on the ability of Cal-33 and JHU-SCC-011 cells
to cross the Matrigel, a reconstitute basal membrane using xCELLigence RTCA technology, were examined (26). The Cal-33 and JHU-SCC-011 cells treated with diluents (AdoMet control) or 300 µM AdoMet, toward serum-free medium (control) or medium containing 10% FBS as a source of chemottractant. Matrigel invasion was monitored for 24 h as changes in the Delta Cell Index (calculated as function of the Cell Index at time=0) using the xCELLigence system. On the right, slopes representing the change rate of Cell Indexes generated in the 3 to 20-h timeframe are shown. Data represent the means ± SD from 2 experiments performed in quadruplicate. *P<0.0001 vs. FBS. HNSCC, head and neck squamous cell carcinoma; AdoMet, S-adenosyl-L-methionine.

Figure 4. Effects of AdoMet on the invasion of HNSCC cells on Matrigel. Invasion of (A) Cal-33 and (B) JHU-SCC-011 cells on Matrigel treated for the indicated time periods with diluents (AdoMet control) or 300 µM AdoMet, toward serum-free medium (control) or medium containing 10% FBS as a source of chemottractant. Matrigel invasion was monitored for 24 h as changes in the Delta Cell Index (calculated as function of the Cell Index at time=0) using the xCELLigence system. On the right, slopes representing the change rate of Cell Indexes generated in the 3 to 20-h timeframe are shown. Data represent the means ± SD from 2 experiments performed in quadruplicate. *P<0.0001 vs. FBS. HNSCC, head and neck squamous cell carcinoma; AdoMet, S-adenosyl-L-methionine.

Taken together, these data highlight the inhibitory effect of AdoMet on the migratory and invasive ability of HNC cells, raising the possibility that AdoMet may be considered, not only as a pro-apoptotic drug for the treatment of HNSCC, but also as a good candidate for preventing the cell invasive ability. AdoMet downregulates the levels of proteins involved in migration and invasion processes. The metastatic process consists of a series of sequential, interrelated steps, including tumor cell detachment from the primary tumor, increased motility and invasion, proteolysis and resistance to apoptosis. To further examine the effects of AdoMet treatment on the motility and invasiveness of HNSCC cells, the main migration and invasion markers characterizing the epithelial-mesenchymal transition (EMT) process, such as E-cadherin and N-cadherin, belonging to a family of transmembrane glycoproteins that mediate cell-cell adhesions, and vimentin, a protein that
plays a significant role in anchoring organelles in the cytosol, were examined by western blot analysis (Fig. 5). The analysis revealed a marked concentration-dependent decrease in the N-cadherin and vimentin levels, and a concomitant increase in E-cadherin levels in the Cal-33 and JHU-SCC-011 cells exposed to 200 and 300 µM AdoMet for 24 h, as compared with the control (untreated cells) (Fig. 5). In addition, according to the cell invasion data, treatment with 200 and 300 µM AdoMet for 24 h led to a clear-cut reduction in the levels of the uPA, MMP2 and MMP9 proteolytic enzymes in both the Cal-33 and JHU-SCC-011 cell lysates (Fig. 5). Moreover, to further investigate the mechanisms underlying the inhibitory effects...
of AdoMet on the invasive and migratory ability of Cal-33 and JHU-SCC-011 cells, several cancer-related signaling pathways associated with invasion and migration were examined by western blot analysis. The results revealed that the sulfonium compound induced a decrease in the p-AKT/AKT, p-SMAD2/SMAD2 and p-SMAD3/SMAD3 ratios, and a downregulation in the expression of β-catenin (Fig. 5).

AdoMet synergistically enhances the cDDP-induced inhibition of cell migration. In a previous study by the authors, the synergistic effect of AdoMet in association with cDDP, an agent commonly used in cancer therapy, in inhibiting Cal-33 cell proliferation and in enhancing cell apoptosis, was demonstrated (13). It was found that the optimal combination of the two drugs, highly synergistic with the CalcuSyn calculation, corresponded to 200 µM AdoMet and 0.18 µM cDDP following 72 h of treatment. In the present study, in order to examine the synergistic effect induced by the AdoMet/cDDP combination on the migration process, the wound closures in the Cal-33 and JHU-SCC-011 cells treated with 300 µM AdoMet plus/minus 0.18 or 0.36 µM cDDP for 24 and 48 h, respectively, were examined. As shown in Fig. 6, the wound width with the combination treatments were significantly greater compared to those of the control or to the single compound treatments with wound closure percentage values of 23 and 31% in the Cal-33 and JHU-SCC-011 cells, respectively compared to 100% of the control. The obtained results indicated that, when used in combination, AdoMet and cDPP were more effective in reducing cell migration than individual agents confirming that AdoMet potentiates the cytotoxic effects of cDDP on HNSCC.

Discussion
Although the majority of cancer-associated mortality cases are caused by metastatic cancer rather than primary tumors, this biology complex process remains the least understood
feature of cancer. The biochemical mechanisms and processes involved in metastatic cancer have been designed, such as potential targets for the prevention and inhibition of metastasis. HNSCC represents one of the most common types of tumor worldwide and almost 60% of patients with HNSCC develop metastases that limit their survival (1-4). Adverse toxic side-effects of chemotherapy during HNSCC treatment have shifted the focus towards anticancer natural compounds as a valuable source of novel and less toxic drugs that can be useful to block both tumor growth and metastatic spread of cancer cells.

The naturally occurring sulfur-containing nucleoside, AdoMet, is an important and ubiquitous biomolecule with a variety of biological functions, and the majority of these have been fully elucidated. AdoMet is one of the most frequently metabolites involved in intermediary metabolism, since it is the principal biological methyl donor in the cytosol of all mammalian cells. AdoMet also plays a role in other processes, such as transsulfuration reactions and polyamine synthesis (5-7).

Despite emerging data from the literature on the anti-proliferative and anti-metastatic effects exerted by AdoMet in a variety of cancer cells are accumulating (8-13), currently, only limited data are available on the molecular mechanisms underlying the anticancer effects of AdoMet on HNSCC (13), and the role of AdoMet in the invasion and migration of HNSCC has not been investigated to date, at least to the best of our knowledge.

Firstly, the present study evaluated the effect of AdoMet on cell viability. Cell cycle progression and its regulation is the key event of cell proliferation. In cancer cells, a number of cell cycle regulators, including p53, are mutated or inactivated, leading to uncontrolled cell proliferation. Thus, the ability of natural compounds with anticancer properties to reduce malignant growth by controlling cell cycle events, may be considered useful for cancer treatment and prevention.

In the current study, it was demonstrated that AdoMet induced a marked cell cycle arrest at the G2/M phase in Cal-33 cells, while it significantly increased the percentage of JHU-SCC-011 cells in the S phase. G2/M arrest is largely mediated through the phosphorylation of cdc25C, a p53-independent mechanism, and the consequential maintenance of cyclin-dependent kinases 1/cyclin B in the phosphorylated and inhibited state (27,28). Of note, the present study found that AdoMet-induced G2/M phase arrest in Cal-33 cells was accompanied by a notable increase in the level of phospho-cdc25C protein. Moreover, it was found that AdoMet treatment modulated the cell cycle by downregulating the levels of cyclin D1, E1, A2, B1 and p21, while leaving the p53 levels unmodified, suggesting that cell cycle arrest at the G2/M and S phase in the Cal-33 and JHU-SCC-011 cells, respectively, is a p53/p21-independent process.

DNA methylation represents one of the most well-studied epigenetic processes in tumors (29). The ability of the sulfonium compound to regulate genes responsible for cell invasion and

Figure 7. Schematic diagram summarizing the effects of AdoMet on the main markers of migration and invasion processes in HNSCC. HNSCC, head and neck squamous cell carcinoma; AdoMet, S-adenosyl-L-methionine; MMP, matrix metalloproteinase; uPA, urokinase-type plasminogen activator; SMAD, small mothers against decapentaplegic.
metastasis, has been well documented in human cancer and in particular, AdoMet has been reported to induce the downregulation of pro-metastatic genes, including uPA and MMPs (16,19). Accordingly, the present study found that AdoMet treatment decreased the uPA, MMP2 and MMP9 content in the Cal-33 and JHU-SCC-011 cells. uPA is an extracellular serine protease implicated in tumor invasion and metastasis processes either directly by degrading extracellular matrix barriers or indirectly, by inducing plasmin-dependent activation of latent MMPs (30). Similar to uPA, MMPs are involved in extracellular matrix remodeling and degradation and play a role in modulating all stages of carcinogenesis, from tumor initiation to metastasis (31). The AdoMet-induced decrease in the levels of uPA, MMP2 and MMP9 are in good accordance with the reduced invasive ability on Matrigel of both the Cal-33 and JHU-SCC-011 cells treated with the sulfonium compound. It was found that AdoMet did not affect basal cell invasion, as compared to the untreated cells. However, despite different cell invasive abilities, both cell lines responded to AdoMet treatment to a similar extent, as 300 µM AdoMet reduced the invasion of Cal-33 and JHU-SCC-011 cells on Matrigel by 73 and 63%, respectively. Although the present study did not examine the effect of AdoMet on the invasive ability of HNSCC in animal models, to the best of our knowledge, this is first study to report the inhibitory effects of AdoMet on the invasive abilities of two HNSCC lines, Cal-33 and JHU-SCC-011 cells. The experimental evidence obtained by the in vitro experiments however, needs to be verified and broadened by further in vivo studies in the future.

The present study also demonstrated that AdoMet reduced the migration of both HNSCC cell lines. Notably, the inhibitory effect of AdoMet on cell migration could not be due to apoptosis for the following reasons: i) treatment of the Cal-33 and JHU-SCC-011 cells with 300 µM AdoMet for 24 and 48 h, respectively, did not trigger appreciable apoptotic cell death in both cell lines; ii) the cytoskeleton machinery, which is required for cell migratory ability, was not modified by AdoMet treatment. Moreover, in line with the AdoMet-dependent decrease in cell motility and invasiveness, it was found that AdoMet treatment led to an appreciable decrease in the levels of N-cadherin and vimentin mesenchymal makers, and to a concomitant increase in the levels of the E-cadherin epithelial maker in HNSCC.

The characterization of the main growth and survival pathways involved in HNSCC seems to be the same in spite of the variety of risk factors and anatomical locations of origin. The molecular signaling pathways that appear to be most relevant to HNSCC are summarized in Fig. 7. The ability of AdoMet to inhibit migration and invasion processes at multiple levels, stimulates great interest for future investigations and suggests that AdoMet may be an attractive candidate for the development of drugs against HNSCC.

The multi-targeted effects exerted by AdoMet in HNSCC are summarized in Fig. 7. The ability of AdoMet to inhibit migration and invasion processes at multiple levels, stimulates great interest for future investigations and suggests that AdoMet may be an attractive candidate for the development of drugs against HNSCC.

Finally, to emphasize the potential role of AdoMet as an anticancer molecule, the present study analyzed the wound closure effectiveness of the combination of sulfonium compound with cDDP, a characteristic platinum complex already applied in HNSCC alone or in synergy with other drugs for therapeutic purposes (51). In a previous study on Cal-33 cells, it was demonstrated that after 72 h, combined AdoMet/cDDP treatment resulted in a potent synergistic pro-apoptotic effect on Cal-33 cells; the use of AdoMet at the 200 mM concentration meant that the concentration of active cDDP was able to be reduced up to 0.18 µM, the lowest concentration used in combination with other natural compounds (13).
The present study demonstrates, for the first time, to the best of our knowledge, that AdoMet and cDPP synergize to prevent wound closure in Cal-33 and JHU-SCC-011 cells. Indeed, by a wound healing assay, it was found that, after 24 h, the wounded areas in the combination treatment groups were significantly larger as compared to those of the control or single compound treatment groups. The mechanism of action of cDPP has been linked to its ability to induce DNA damage via the formation of crosslinks with the purine bases on DNA, interfering with DNA repair mechanisms, and subsequently inducing the apoptosis of cancer cells. Moreover, multiple signal transduction pathways are activated by cDPP-induced genotoxic stress, through the activation of MAPK pathways, particularly JNK and ERK (13,52). These mechanisms may contribute to either apoptosis or chemoresistance. Furthermore, it was recently demonstrated that cDPP has the ability to interfere with the proliferation, migration and invasion of nasopharyngeal carcinoma cells in vitro by suppressing the Wnt/β-catenin/Endothelin-1 axis via the activation of the B cell translocation gene 1 (52).

Taken together, these findings strongly support the notion that AdoMet may be considered as an anticancer agent in virtue of its ability to prevent the proliferation, migration and invasion of HNSCC cells. Furthermore, the fact that AdoMet effectively improves the cDPP-dependent inhibition of cell migration, provides the basis for including this physiological compound in the therapeutic management of metastatic HNSCC. Moreover, AdoMet has been available as a dietary supplement in the United States since 1999. Reviews of clinical studies to date have indicated that, at pharmacological doses, AdoMet has a low incidence of side-effects with an excellent record of tolerability. Moreover, no toxic or anti-proliferative effects have been reported in normal, non-tumorigenic cells (53-55). Thus, it is conceivable that the concentrations of AdoMet that would inhibit cancer cell proliferation, migration and invasion processes, utilized in the present, as well as in other studies, may be useful for further trials on patients.

Acknowledgements
Not applicable.

Funding
The present study was partially supported by Programme Valere 2019 (VANVITELLI per la Ricerca; Università della Campania ‘Luigi Vanvitelli’).

Availability of data and materials
All data generated or analyzed during this study are included in this published article or are available from the corresponding author on reasonable request.

Authors’ contributions
MPo and LM conceived the study, designed the experiments, analyzed the data and drafted the manuscript. GC and MVC contributed to the design of the study and to the data analysis and reviewed the manuscript. MPa and FV performed the experiments, analyzed the data and prepared the figures; MM contributed to the design and accomplishment of the experiments based on Matrigel invasion and on cytoskeletal organization. All authors contributed to the revision of the manuscript and read and approved the final version of manuscript.

Ethics approval and consent to participate
Not applicable.

Patient consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

References
1. Chin D, Boyle GM, Poreddu S, Theile DR, Parsons PG and Coman WB: Head and neck cancer: Past, present and future. Expert Rev Anticancer Ther 6: 1111-1118, 2006.
2. Marur S and Forastiere AA: Head and neck squamous cell carcinoma: Update on epidemiology, diagnosis, and treatment. Mayo Clin Proc 91: 386-396, 2016.
3. Kumar M, Nanavati R, Modi TG and Dobariya C: Oral cancer: Etiology and risk factors: A review. J Cancer Res Ther 12: 458-465, 2016.
4. Kulikarni P and Saxena U: Head and neck cancers, the neglected malignancies: Present and future treatment strategies. Expert Opin Ther Targets 18: 351-354, 2014.
5. Lu SC: S-Adenosymethylionine. Int J Biochem Cell Biol 32: 391-395, 2000.
6. Mato MJ, Corrales FI, Lu SC and Avila MA: S-Adenosymethylionine: A control switch that regulates liver function. FASEB J 16: 15-26, 2002.
7. Fontecave M, Atta M and Mulliez E: S-Adenosymethylionine: Nothing goes to waste. Trends Biochem Sci 29: 243-249, 2004.
8. Ansorena E, Garcia-Trevijano ER, Martinez-Chantar ML, Huang ZZ, Chen L, Mato JM, Iaburu M, Lu SC and Avila MA: S-Adenosymethylionine and methylthioadenosine are anti-apoptotic in cultured rat hepatocytes but pro-apoptotic in human hepatoma cells. Hepatol 35: 274-280, 2002.
9. Lu SC and Mato JM: S-Adenosymethylionine in cell growth, apoptosis and liver cancer. J Gastroenterol Hepatol 23 (Suppl 1): S73-S77, 2008.
10. Martinez-Lopez N, Varela-Rey M, Ariz U, Embade N, Vazquez-Chantada M, Fernandez-Ramos D, Gomez-Santos L, LuSC, MatoJMandMartinez-ChantarML: S-Adenosymethylionine and proliferation: New pathways, new targets. Biochem Soc Trans 36: 848-852, 2008.
11. Ilisso CP, Sapio L, Delle Cave D, Miliano M, Spin a, Cacciapuoti G, Naviglio S and Porcelli M: S-Adenosymethylionine affects ERK1/2 and Stat3 pathways and induces apoptosis in osteosarcoma cells. J Cell Physiol 231: 428-435, 2016.
12. Cave DD, Desiderio V, Mosca L, Ilisso CP, Mele L, Caraglia M, Cacciapuoti G and Porcelli M: S-Adenosymethylionine-mediated apoptosis is potentiated by autophagy inhibition induced by chloroquine in human breast cancer cells. J Cell Physiol 235: 1370-1383, 2018.
13. Mosca L, Pagano M, Ilisso CP, Cave DD, Desiderio V, Mele L, Caraglia M, Cacciapuoti G and Porcelli M: AdoMet triggers apoptosis in head and neck squamous cancer by inducing ER stress and potentiates cell sensitivity to cisplatin. J Cell Physiol 234: 13277-13291, 2019.
14. Steeg PS: Tumour metastasis: Mechanistic insights and clinical challenges. Nat Med 12: 895-904, 2006.
15. Braakhuis BJ, Senft A, de Bree R, de Vries J, Ylstra B, Cloos J, Kuik DJ, Leemans CR and Brakenhoff RH: Expression profiling and prediction of distant metastases in head and neck squamous cell carcinoma. J Clin Pathol 59: 1254-1260, 2006.
16. Pakneshan P, Syzf M, Farias-Eisner R and Rabbani SA: Reversal of the hypomethylation status of urokinase (uPA) promoter blocks breast cancer growth and metastasis. J Biol Chem 279: 22167-22178, 2004.

17. Shukeir N, Pakneshan P, Chen G, Syzf M and Rabbani SA: Alteration of the methylation status of tumor-promoting genes decreases prostate cancer cell invasiveness and tumorigenesis in vitro and in vivo. Cancer Res 66: 9202-9210, 2006.

18. Chik F, Machnes Z and Syzf M: Synergistic anti-breast cancer effect of a combined treatment with the methyl donor S-adenosylmethionine and the DNA methylation inhibitor 5-aza-2'-deoxycytidine. Carcinogenesis 35: 138-144, 2014.

19. Hussain Z, Khan MI, Shahid M and Almajhdi FN: S-adenosylmethionine, a methyl donor, up regulates tissue inhibitor of metalloproteinase-2 in colorectal cancer. Genet Mol Res 12: 1106-1118, 2013.

20. Parashar S, Cheishvili D, Arakelian A, Hussain Z, Tanvir I, Khan HA, Syzf M and Rabbani SA: S-Adenosylmethionine blocks osteosarcoma cells proliferation and invasion in vitro and tumor metastasis in vivo. Therapeutic and diagnostic clinical applications. Cancer Med 4: 732-744, 2015.

21. Liu Y, Li T, Liu L, Gao Q, Shen G, Qian X. S-Adenosylmethionine synergistically enhances the antimtumor effect of gemcitabine against pancreatic cancer through JAK2/STAT3 pathway. Naunyn Schmiedebers Arch Pharmacol 392: 615-622, 2019.

22. Sun W, Zhong C, Yin J, Li Y, Yin Y, Liu Y, Liu Y, Wang H and Huang Z: Synergistic Effects of SAM and selenium compounds on proliferation, migration and adhesion of HeLa cells. Anticancer Res 37: 4343-4441, 2017.

23. Verme R, Haenec C, Steffens-Nakkien H and Reutelingsperger C: A novel assay for apoptosis. Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluoroscien labelled Annexin V. J Immunol Methods 184: 39-51, 1995.

24. Bradford MM: Rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72: 248-254, 1976.

25. Fratangelo F, Camerlingo R, Carriero MV, Pirozzi G, Palmieri G, Mancuso A, Lo Cicero A, Greco M, Mastrocola M, Magi L, Marcelli M and Minico M: Urokinase receptor-derived cyclic peptide [SRSRY] suppresses breast cancer cell invasion and motility. Curr Pharm Des 17: 1944-1961, 2011.

26. Dasari S and Tchounwou PB: Cisplatin in cancer therapy: Molecular mechanisms of action. Eur J Pharmacol 740: 364-378, 2014.

27. Yin P, Song G and Jiang Z: Cisplatin suppresses proliferation, migration and invasion of nasopharyngeal carcinoma cells in vitro by repressing the Wnt/beta-catenin/Endothelin-1 axis via activating B cell translocation gene 1. Cancer Chemother Pharmacol 81: 663-672, 2018.

28. Luo J, Li YN, Wang F, Zhang WM and Geng X: Effect of ABT-888 on the apoptosis, motility and invasiveness of BRAF-mutant melanoma cells. Int J Oncol 53: 1149-1159, 2018.

29. Inangsi V, Bifulco K, Yousif AM, Rangone C, Motti ML, Rea D, Minopoli M, Botti G, Scognamiglio G, Fazioli F, et al: The urokinase receptor-derived cyclic peptide [SRSRY] suppresses neovascularization and intravasation of osteosarcoma and chondrosarcoma cells. Oncotarget 7: 54014-54025, 2016.

30. Malumbres M and Barbacid M: Mammalian cyclin-dependent kinases. Trends Biochem Sci 30: 630-641, 2005.

31. Gutierrez GJ, Tsuji T, Cross JV, Davis RJ, Templeton DJ, Jiang W, Malumbres M and Barbacid M: Mammalian cyclin-dependent kinases. Trends Biochem Sci 30: 630-641, 2005.

32. Kessenbrock K, Plaks V and Werb Z: Matrix metalloproteinases: activator and the generation of inhibitors of urokinase activity and signaling. Curr Pharm Des 17: 1944-1961, 2011.

33. Kessenbrock K, Plaks V and Werb Z: Matrix metalloproteinases: activator and the generation of inhibitors of urokinase activity and signaling. Curr Pharm Des 17: 1944-1961, 2011.

34. Luo J, Li YN, Wang F, Zhang WM and Geng X: S-adenosylmethionine inhibits the growth of cancer cells by reversing the hypomethylation status of c-myc and H-ras in human gastric cancer and colon cancer. Int J Biochem Cell Biol 42: 809-812, 2010.

35. Liu J, Wang Y, Pan Q, Su Y, Zhang Z, Han J, Zhu X, Tang C and Hu D: Wnt/beta-catenin pathway forms a negative feedback loop during TGF-beta1 induced human normal skin fibroblast-to-myofibroblast transition. J Dermatol Sci 65: 38-49, 2012.

36. Boldbazzar A, Lee S, Han S, Jeong AL, Ka HI, Buyanravijik S, Lee JH, Lim JS, Lee MS and Yang Y: Eupatolide inhibits the TGF-beta1-induced migration of breast cancer cells via downregulation of SMAD3 phosphorylation and transcriptional repression of Erk and ERK5. Oncol Rep 35: 6031-6038, 2016.

37. Xu W, Yang Z and Lu N: A new role for the PI3K/Akt signaling pathway in the epithelial-mesenchymal transition. Cell Adh Migr 9: 317-324, 2015.

38. Feng XH and Derynck R: Specificity and versatility in TGF-beta signaling through Smads. Annu Rev Cell Dev Biol 21: 659-693, 2005.

39. Suryanamthu S, Baker D, Ten Dijke P and Iyengar PV: Epigenetic reprogramming of TGF-beta signaling in breast cancer. Cancer Res (Basel) 11: E726, 2020.

40. Guo W, Flanagan J, Basu R, Kulkarni J, Liang L and Bhasin S: The effects of myostatin on adipogenic differentiation of human bone marrow-derived mesenchymal stem cells are mediated through cross-communication between Smad3 and Wnt/beta-catenin signaling pathway. J Biol Chem 283: 9136-9145, 2008.

41. Minoo P and Li C: c-Jun-NH(2)-terminal kinase: a cross-talk transforming growth factor-beta and Wingless/Int pathways in lung development and disease. Int J Biochem Cell Biol 42: 809-812, 2010.

42. Lu G, Wang Y, Pan Q, Su Y, Zhang Z, Han J, Zhu X, Tang C and Hu D: Wnt/beta-catenin pathway forms a negative feedback loop during TGF-beta1 induced human normal skin fibroblast-to-myofibroblast transition. J Dermatol Sci 65: 38-49, 2012.

43. Boldbazzar A, Lee S, Han S, Jeong AL, Ka HI, Buyanravijik S, Lee JH, Lim JS, Lee MS and Yang Y: Eupatolide inhibits the TGF-beta1-induced migration of breast cancer cells via downregulation of SMAD3 phosphorylation and transcriptional repression of Erk and ERK5. Oncol Rep 35: 6031-6038, 2016.

44. Qin Y, Yang Z and Lu N: A new role for the PI3K/Akt signaling pathway in the epithelial-mesenchymal transition. Cell Adh Migr 9: 317-324, 2015.